Ralliant Corporation (NYSE:RAL) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts remain broadly positive: Twelve analysts give Ralliant a consensus “Moderate Buy” rating, with an average 12-month price target of $75.70 versus the stock’s $69.42 opening price.
• Quarterly results beat expectations: Ralliant reported EPS of $0.68, above the $0.63 consensus estimate, on revenue of $567.8 million. Management guided to fiscal 2026 EPS of $2.76–$2.90.
• Shares have pulled back but institutional interest is strong: Ralliant stock was reported down 3.5%, while major investors including BlackRock, Viking Global and State Street established or expanded positions. The company also declared a quarterly dividend of $0.05 per share.

Ralliant Corporation (NYSE:RAL - Get Free Report) has received an average rating of "Moderate Buy" from the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $75.70.

A number of research analysts have issued reports on the company. Citigroup lifted their target price on Ralliant from $81.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Truist Financial restated a "buy" rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Oppenheimer lifted their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an "outperform" rating in a report on Wednesday, May 13th. Evercore assumed coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an "outperform" rating and a $80.00 price objective for the company. Finally, Morgan Stanley increased their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a research note on Tuesday, June 23rd.

Ralliant Stock Down 3.5%

NYSE RAL opened at $69.42 on Wednesday. The business has a fifty day moving average price of $68.94 and a two-hundred day moving average price of $55.70. The stock has a market capitalization of $7.68 billion, a PE ratio of -6.40, a PEG ratio of 2.69 and a beta of 1.61. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RAL - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts expect that Ralliant will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant's dividend payout ratio is -1.84%.

Insiders Place Their Bets

In related news, SVP Karen M. Bick sold 6,062 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the sale, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. The trade was a 16.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the transaction, the chief executive officer directly owned 251,967 shares of the company's stock, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by corporate insiders.

Institutional Trading of Ralliant

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Ralliant in the 2nd quarter valued at approximately $1,039,481,000. Dodge & Cox grew its holdings in Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company's stock worth $621,849,000 after acquiring an additional 1,434,376 shares during the last quarter. Viking Global Investors LP acquired a new position in Ralliant in the 2nd quarter valued at approximately $257,200,000. Millennium Management LLC increased its position in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the period. Finally, State Street Corp acquired a new position in Ralliant in the 2nd quarter valued at approximately $213,096,000.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source